This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Education
  • Quiz
  • Oct/Nov 2019 Quiz

Oct/Nov 2019 Quiz

1 October 2019 | EYE - General
Share This

 

History

 

  • A 62-year-old female patient was referred for rapid growth of a left periorbital soft tissue lesion with proptosis.
  • Her past medical history included: hypertension, hyperlipidaemia and bipolar disorder.
  • On examination: vision in the affected eye was hand movements, right eye was 6/9 aided; there was a palpable left periorbital mass; marked anterolateral proptosis and fixed globe with no extraocular movements.
  • A left lateral canthotomy with upper and lower lid cantholysis was performed and an incisional biopsy of the lesion was sent for ophthalmic pathology assessment.
  • Macroscopic examination revealed a gelatinous pale mass measuring 12x8x6mm.
  • In the meantime, MRI head and orbits with contrast (Figures 1a and b) showed a left orbital tumour (white arrows) measuring 7x5.4x6cm displacing the globe anterolaterally and extending to the paranasal sinuses, left nasal cavity with bifrontal extradural extension.

 

 


Questions

 

  1. Figures 2a and b show a representative H&E section of the lesion. How can this be described?
  2. What immunohistochemical stains would help?
  3. Figures 3-6 demonstrate positive immunostaining for select markers. What is the most likely diagnosis?
  4. What further management is advised?

 

 

 

 

 

 

 

 

 

 


Answers

 

1. Figure 2 shows extensive infiltration of lesional tissue with medium-sized cells with a high nuclear:cytoplasmic ratio, ‘salt-pepper’ chromatin and scant cytoplasm. There are numerous mitoses (black arrows) and apoptotic bodies (yellow arrows).
2. Histomorphological differentials would include lymphoma, neuroendocrine tumour or carcinoma. Immunohistochemistry would include: lymphoma markers – CD20, CD79a, CD3, CD10, BCL-6 & MUM1; neuroendocrine markers – CD56, synaptophysin and chromogranin; Ki67 growth fraction immunostain; and a pancytokeratin marker AE1/3 to exclude carcinoma.
3. Representative panels show the neoplastic cells staining positively for neuroendocrine markers CD56 and synaptophysin, characteristic ‘dot-like’ cytokeratin positivity and high Ki67 growth fraction. Lymphoma markers were all negative. The histomorphologic and immunhistochemical features are consistent with a METASTATIC NEUROENDOCRINE CARCINOMA to the orbit.
4. Full investigation including CT neck, thorax, abdomen and pelvis to locate the primary tumour, extent of disease and staging; neuro-oncology MDT discussion and referral to oncologist. Primary neuroendocrine tumours occur more commonly in the gastrointestinal or bronchopulmonary tracts. In this case, however, there were no lesions found at either of these sites. Furthermore, there were no liver metastases. The tumour may have originated in the ethmoid sinus and represent a primary sino-nasal neuroendocrine carcinoma which had locally invaded the orbit. CT scan revealed possible submandibular lymph node and T9 vertebral metastases. The patient is currently receiving chemotherapy.

 

The section editors would like to acknowledge and thank Mr Austin McCormick and Mrs Jean Hancock, Aintree University Hospital, for providing the clinical details.

 

 

COMMENTS ARE WELCOME

Share This
Originally Published
EYE NEWS VOLUME 26 ISSUE 3 OCTOBER/NOVEMBER 2019
Download the full article
Download Article

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency